NIH delivers gene therapy to the inside of mitochondria; Bio-Path completes toxicity study of its infusion-based cancer candidate;

> NIH researchers have deployed an adeno-associated virus that enters mitochondria to deliver DNA to improve the vision of mice. More

> Bio-Path Holdings successfully completed a Phase Ib toxicity study of its lead compound, Liposomal Grb-2, for patients with advanced acute myeloid leukemia. It uses the company's liposomal delivery technology that enables intravenous infusions. More

Suggested Articles

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.

Australia's University of New South Wales and Uka Tarsadia University in India will join forces to explore contact lenses for ocular drug delivery.